Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele, Merck to Search for SNPs Linked to Cancer Risk, Drug Response

NEW YORK, July 7 (GenomeWeb News) - ParAllele BioScience and Merck plan to co-discover SNPs linked to cancer susceptibility, prognosis, or drug response, the companies said today.

The deal, which is being funded by Merck, ParAllele will use its SNP-genotyping technology to "characterize the genetic changes in tumor samples" identified by the US-based drug maker.

 

Details of the agreement were not disclosed.

 

This is at least the second such collaboration for the companies. Almost exactly two years ago, ParAllele said it would use its lab-in-a-tube technology to develop assays, perform multiplexed genotyping, and provide data analysis for Merck.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.